SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (317)1/8/2003 6:22:48 AM
From: nigel bates  Read Replies (2) of 625
 
You guys who put it in your contest entries

Yes, I was a little disappointed by the 20% rule. <g>

I'm slightly at a loss to explain the muted reaction the the Humira approval, though. Seemed like big news to me, FWIW.

Only possible clouds are competition from ZGEN's fusion protein targeting BlyS (though it's not in the clinic yet), and HGSI looking at Kirin's MAB for TRAIL (-R2)...
and the (very) wild card of Pieczenik's patent 5,866,363 on the IP front.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News